Top

Journal of Hepato-Biliary-Pancreatic Sciences

Published in:

01-07-2012 | Topics

Clinicopathological significance of growth factors and their receptors as potential therapeutic targets for biliary tract carcinoma

Author: Hidenori Ojima

Published in: Journal of Hepato-Biliary-Pancreatic Sciences | Issue 4/2012

Abstract

Biliary tract carcinoma (BTC) has a poor prognosis. However, no standard chemotherapy regimens have been established for inoperable cases or cases of recurrence after surgical resection. Recent molecular biological analysis has shown that epidermal growth factor receptor, human epidermal growth factor receptor 2, vascular endothelial growth factor, hepatocyte growth factor, c-Met and transforming growth factor-beta could be potential targets for therapy of BTC. It is considered that these molecules are involved in the carcinogenesis, invasion, and progression of BTC. Furthermore, immunohistochemical overexpression of these targets is associated with several clinicopathological factors. This article reviews the clinicopathological significance of these growth factors and their receptors.

Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg. 1995;130:270–6.PubMedCrossRef

Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg. 1999;230:663–71.PubMedCrossRef

Jang JY, Kim SW, Park DJ, Ahn YJ, Yoon YS, Choi MG, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg. 2005;241:77–84.PubMed

Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery. 2005;137:396–402.PubMedCrossRef

Ieta K, Tanaka F, Utsunomiya T, Kuwano H, Mori M. CEACAM6 gene expression in intrahepatic cholangiocarcinoma. Br J Cancer. 2006;95:532–40.PubMedCrossRef

Khan SA, Thomas HC, Davidson BR, Taylor Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303–14.PubMedCrossRef

Baserga R. Oncogenes and the strategy of growth factors. Cell. 1994;79:927–30.PubMedCrossRef

Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159–67.PubMedCrossRef

Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Natl Rev Mol Cell Biol. 2001;2:127–37.CrossRef

10.

Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98:418–25.PubMedCrossRef

11.

Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 2005;206:356–65.PubMedCrossRef

12.

Altimari A, Fiorentino M, Gabusi E, Gruppioni E, Corti B, D’Errico A, et al. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig Liver Dis. 2003;35:332–8.PubMedCrossRef

13.

Ito Y, Takeda T, Sasaki Y, Sakon M, Yamada T, Ishiguro S, et al. Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract. 2001;197:95–100.PubMedCrossRef

14.

Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Sugimachi K, Tsuneyoshi M. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology. 2002;40:269–78.PubMedCrossRef

15.

Ukita Y, Kato M, Terada T. Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. J Hepatol. 2002;36:780–5.PubMedCrossRef

16.

Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, et al. Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment. Cancer Sci. 2010;101:882–8.PubMedCrossRef

17.

Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, et al. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer. 2011;105:131–8.PubMedCrossRef

18.

Yoshikawa D, Ojima H, Kokubu A, Ochiya T, Kasai S, Hirohashi S, et al. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer. 2009;100:1257–66.PubMedCrossRef

19.

Tang D, Nagano H, Yamamoto H, Wada H, Nakamura M, Kondo M, et al. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep. 2006;15:525–32.PubMed

20.

Benckert C, Jonas S, Cramer T, Von Marschall Z, Schäfer G, Peters M, et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res. 2003;63:1083–92.PubMed

21.

Hida Y, Morita T, Fujita M, Miyasaka Y, Horita S, Fujioka Y, et al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res. 1999;19:2257–60.PubMed

22.

Shirabe K, Shimada M, Tsujita E, Aishima S, Maehara S, Tanaka S, et al. Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis. Am J Surg. 2004;187:538–42.PubMedCrossRef

23.

Möbius C, Demuth C, Aigner T, Wiedmann M, Wittekind C, Mössner J, et al. Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2007;33:1025–9.PubMedCrossRef

24.

Yokomuro S, Tsuji H, Lunz JG 3rd, Sakamoto T, Ezure T, Murase N, et al. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology. 2000;32:26–35.PubMedCrossRef

25.

Liu Z, Sakamoto T, Ezure T, Yokomuro S, Murase N, Michalopoulos G, et al. Interleukin-6, hepatocyte growth factor, and their receptors in biliary epithelial cells during a type I ductular reaction in mice: interactions between the periductal inflammatory and stromal cells and the biliary epithelium. Hepatology. 1998;28:1260–8.PubMedCrossRef

26.

Napoli J, Prentice D, Niinami C, Bishop GA, Desmond P, McCaughan GW. Sequential increases in the intrahepatic expression of epidermal growth factor, basic fibroblast growth factor, and transforming growth factor beta in a bile duct ligated rat model of cirrhosis. Hepatology. 1997;26:624–33.PubMed

27.

Hida Y, Morita T, Fujita M, Miyasaka Y, Horita S, Fujioka Y, et al. Clinical significance of hepatocyte growth factor and c-Met expression in extrahepatic biliary tract cancers. Oncol Rep. 1999;6:1051–6.PubMed

28.

Zhang YW, Su Y, Volpert OV, Vande WGF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA. 2003;100:12718–23.PubMedCrossRef

29.

Weidner KM, Sachs M, Birchmeier W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol. 1993;121:145–54.PubMedCrossRef

30.

Furge KA, Zhang YW, Vande WGF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene. 2000;19:5582–9.PubMedCrossRef

31.

Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 2008;27:85–94.PubMedCrossRef

32.

Terada T, Nakanuma Y, Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol. 1998;29:175–80.PubMedCrossRef

33.

Shao J, Sheng H, Aramandla R, Pereira MA, Lubet RA, Hawk E, et al. Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis. 1999;20:185–91.PubMedCrossRef

34.

Matsuzaki K, Date M, Furukawa F, Tahashi Y, Matsushita M, Sakitani K, et al. Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma. Cancer Res. 2000;60:1394–402.PubMed

35.

Zen Y, Harada K, Sasaki M, Chen TC, Chen MF, Yeh TS, et al. Intrahepatic cholangiocarcinoma escapes from growth inhibitory effect of transforming growth factor-beta1 by overexpression of cyclin D1. Lab Invest. 2005;85:572–81.PubMedCrossRef

36.

Shimizu T, Yokomuro S, Mizuguchi Y, Kawahigashi Y, Arima Y, Taniai N, et al. Effect of transforming growth factor-beta1 on human intrahepatic cholangiocarcinoma cell growth. World J Gastroenterol. 2006;12:6316–24.PubMed

Title: Clinicopathological significance of growth factors and their receptors as potential therapeutic targets for biliary tract carcinoma
Author: Hidenori Ojima
Publication date: 01-07-2012
Publisher: Springer Japan
Published in: Journal of Hepato-Biliary-Pancreatic Sciences / Issue 4/2012
Print ISSN: 1868-6974
Electronic ISSN: 1868-6982
DOI: https://doi.org/10.1007/s00534-011-0497-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinicopathological significance of growth factors and their receptors as potential therapeutic targets for biliary tract carcinoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Preoperative MRCP to detect choledocholithiasis in acute calculous cholecystitis

Effect of the silk protein sericin on cryopreserved rat islets

Clinical and pathological analysis of 27 patients with combined hepatocellular-cholangiocarcinoma in an Asian center

Negative impact of low body mass index on surgical outcomes after hepatectomy for hepatocellular carcinoma

Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction